key: cord-0863361-gusamhl3
authors: Mühlemann, Barbara; Thibeault, Charlotte; Hillus, David; Helbig, Elisa T.; Lippert, Lena J.; Tober-Lau, Pinkus; Schwarz, Tatjana; Müller, Marcel A.; Witzenrath, Martin; Suttorp, Norbert; Sander, Leif E.; Drosten, Christian; Jones, Terry C.; Corman, Victor M.; Kurth, Florian
title: Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalised COVID-19 patients - results from a prospective observational study
date: 2021-06-15
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.06.008
sha: 68d86bcb803bd3e1e68521a3f7233876d7692a52
doc_id: 863361
cord_uid: gusamhl3

OBJECTIVES: Dexamethasone has become standard of care for severe coronavirus disease 2019 (COVID-19), but its virological impact is poorly understood. The objectives of this work were to characterise the kinetics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) concentration in the upper respiratory tract (URT) and the antibody response in patients with (D(+)) and without (D(-)) dexamethasone treatment. METHODS: Data and biosamples from hospitalised patients with severe COVID-19, enrolled between March 4(th) and December 11(th), 2020, in a prospective observational study, were analysed. SARS-CoV-2 virus concentration in serial URT samples was measured using RT-PCR. SARS-CoV-2-specific Immunoglobulin A and G (IgA and IgG) were measured in serum samples using S1-ELISA. RESULTS: We compared 101 immunocompetent patients who received dexamethasone according to the inclusion criteria and dosage determined in the RECOVERY trial to 93 immunocompetent patients with comparable disease severity from the first months of the pandemic, who had not been treated with dexamethasone or other glucocorticoids. We found no inter-group differences in virus concentration kinetics, duration of presence of viral loads >10(6) viral copies/mL (D(+): median 17 days (IQR 13-24), D(-): 19 days (IQR 13-29)), or time from symptom onset until seroconversion (IgA: D(+): median 11.5 days (IQR 11-12), D(-): 14 days (IQR 11.5-15.75); IgG: D(+): 13 days (IQR 12-14.5), D(-): 12 days (IQR 11-15)). CONCLUSION: Dexamethasone does not appear to lead to a change in virus clearance or a delay in antibody response in immunocompetent patients hospitalised with severe COVID-19.

and December 11 th , 2020, in a prospective observational study, were analysed. SARS-CoV-2 virus 50 concentration in serial URT samples was measured using RT-PCR. SARS-CoV-2-specific 51

Immunoglobulin A and G (IgA and IgG) were measured in serum samples using S1-ELISA. 52

We compared 101 immunocompetent patients who received dexamethasone according to the 54 inclusion criteria and dosage determined in the RECOVERY trial to 93 immunocompetent patients 55 with comparable disease severity from the first months of the pandemic, who had not been treated 56 with dexamethasone or other glucocorticoids. We found no inter-group differences in virus 57 concentration kinetics, duration of presence of viral loads >10 6 viral copies/mL (D + : median 17 days 58

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection has a clinical 66 spectrum ranging from asymptomatic to severe disease [1] . Inflammation-mediated lung injury plays 67 a crucial role in progression to severe Coronavirus disease 2019 (COVID-19). Glucocorticoids are 68 widely used for treatment of infectious and non-infectious diseases involving a dysregulated immune 69 response. In severe COVID-19, dexamethasone showed beneficial effects when administered >7 days 70 after symptom onset [2] and became the standard of care [3] . However, the impact of dexamethasone 71 on viral concentration and the adaptive immune response is not well studied [4] . We analysed the 72 impact of dexamethasone on SARS-CoV-2 RNA kinetics and antibody response in a prospective 73 observational cohort of hospitalised immunocompetent COVID-19 patients. 74 

(URT) [8] and is given here as log 10 RNA copies per 1 mL sampling buffer. In routine testing, a 91 weekly RT-PCR was performed, with test frequency sometimes increasing towards the end of the 92 isolation period. All patients with at least one positive RT-PCR test result were included in the 93 analysis. RNA measurements taken up to 40 days after admission were included for statistical 94

Enzyme-linked immunosorbent assay for the detection of Immunoglobulin G and A (IgG and IgA) to 96 the S1 domain of the SARS-CoV-2 spike protein (S1-ELISA) was performed once per week during 97 hospital stay, as described elsewhere [9] , with a median of four measurements performed per patient. 98

All patients with at least one reactive S1-ELISA test (optical density (OD) ratio >1.1) were included 99 in the analysis (n=174). S1-ELISA OD ratios were capped at a value of 5. Outliers, defined as patients 100 who seroconverted or reached a threshold OD ratio of five after more than 30 days were excluded 101 (n=5). Distribution of continuous variables is shown as median and interquartile range (IQR). One-hundred and one patients received dexamethasone treatment (D + ) of 6 mg/day orally or 111 intravenously for a median duration of 10 days (IQR 8.5-11), initiated at a median of 7 days (IQR 5-112 10) after symptom onset or 1 day (IQR 0-2) after hospital admission. Ninety-three patients, mostly 113 hospitalised before June 2020, did not receive dexamethasone or other glucocorticoids (D -, Figure  114   S1 ). Eight patients received other glucocorticoids or different daily doses of dexamethasone and were 115 excluded. We found no statistically significant differences between clinical baseline characteristics 116 including duration of symptoms until hospital admission, age, gender, presence of comorbidities, or 117 level of respiratory support at admission in the groups (Tables S1, S2). 118

SARS-CoV-2 RNA concentration kinetics in the URT did not differ between patient groups (Fig.  120   1A) , even though Dpatients had lower RNA concentrations throughout the study than D + patients 121 (Fig. S2) . Similarly, no difference was seen when excluding patients (n=18) with antiviral treatment 122 (Supp Table 1 ). We also found no evidence for differences in the time from symptom onset to the last 123 test with a viral load >10 6 viral copies per mL between patient groups (D + : median 17 days (IQR 13-124 24), D -: median 19 days (IQR 13-29) p=0.37, Fig. 1B) . 125 no difference in time from symptom onset to the first test with an OD ratio ≥5 between D + and D -133 patients (median days from symptom onset to first IgA test with OD ratio ≥5, 13 (IQR 10-16) vs 13 134 (IQR 11-15.5), respectively; p=0.76; median days from onset to first IgG test with OD ratio ≥5, 15 135 (IQR 13-18) vs 15 (IQR 12-16), respectively; p=0.20. Fig. 2C and D) . In this post hoc analysis of patients included in a prospective cohort study we found no difference in 147 SARS-CoV-2 RNA kinetics or humoral immune response in two comparable groups of 148 immunocompetent patients hospitalised with COVID-19, treated with or without dexamethasone. We 149 observed a shorter duration of hospital stay and a trend towards reduced progression to mechanical 150 ventilation and dialysis in the dexamethasone group, yet this observational data may be influenced by 151 factors such as a more strained health-care system in the second pandemic wave. A limitation is the 152 relatively small sample size of our study, particularly with regard to biosamples before 153 seroconversion. We could not adjust for demographic and clinical parameters that may influence 154 antibody kinetics [9] . seroconversion is measured as the time from symptom onset to a reactive S1-ELISA test that is 175 preceded by a non-reactive S1-ELISA test. A) IgA, median duration to seroconversion: D + : 11.5 days 176 (IQR 11-12); D -: 14 days (IQR 11.5-15.75). Seroconversion could be observed in six D + patients and 177 six Dpatients that were initially hospitalised with a non-reactive IgA S1-ELISA result. B) IgG, 178 median duration to IgG seroconversion, D + : 13 days (IQR 12-14.5), D -: 12 days (IQR 11-15). For 179 IgG, 23 D + patients and 15 Dpatients were initially hospitalised with a non-reactive IgG S1-ELISA 180 and later seroconverted. Panels C and D show time from symptom onset to the first test reaching the 181 threshold OD ratio ≥5. Only patients with a first test taken no more than 20 days after symptom onset 182

were included. C) IgA, median duration from symptom onset to first IgA S1-ELISA test with OD 

Nils B. Müller, and Philipp Enghard for obtaining 216 informed consent and biosamples

Wirsching for data collection

Tscheak for contributing to testing and biobanking of samples

Characteristics of SARS-CoV-2 and COVID-19

Dexamethasone in Hospitalized Patients with Covid-19

Outcomes: Systematic Review and Meta-241 analysis

Adaptive immunity to SARS-CoV-2 and COVID-19

Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective 246

COVID-19 patient cohort (Pa-COVID-19)

Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary 250

Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. Front 260 Immunol 2021

Association of 262 corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis

Impact of corticosteroid therapy on 265 outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic 266 review and meta-analysis

Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection

Influence of Corticosteroid Dose on Viral Shedding Duration in Patients With 272

Lack of detrimental effect 274 of corticosteroids on antibody responses to SARS-CoV-2 and viral clearance in patients 275 hospitalized with COVID-19

Virological 278 assessment of hospitalized patients with COVID-2019